Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal esketamine plus oral antidepressant for relapse prevention in adults with treatment-resistant depression
RBR-3dccf6Phase 3Recruiting
- Sponsor
- Clinica Dr Norton Sayeg
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in treatment-resistant depression (TRD) and major depressive disorder (MDD) comparing Esketamine group with Placebo group (2 arms). Started Jul 2015; status: recruiting.
02
Drugs
esketamine
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)
Beyond the preview
Go deeper on RBR-3dccf6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-3dccf6.